Lota Maria Margarita M, Capeding Rosario Z, Garcia Fernando B, Medina John Robert C, Serrano Jeremiah A, Lumangaya Carlo R, Belizario Vicente Y
Department of Medical Microbiology, College of Public Health, University of the Philippines Manila, Manila, Philippines.
Asian Hospital and Medical Center, Muntinlupa, Philippines.
Acta Med Philipp. 2025 Mar 31;59(4):151-158. doi: 10.47895/amp.v59i4.10372. eCollection 2025.
Pneumococcal vaccination has been widely used for the prevention of pneumococcal disease, with two types of vaccines available since 2009. With the World Health Organization (WHO) recommendation of incorporating pneumococcal conjugate vaccines (PCVs) in National Immunization Programs (NIPs) worldwide, a ten-valent PCV (PHiD-CV) was initially introduced in the Philippines in 2012. This, however, transitioned to the use of the 13-valent PCV (Prevnar) subsequent to the recommendation of the Formulary Executive Council in 2014.
This review aimed to present evidence on pneumococcal disease and vaccine inclusion in the Philippine NIP from 2005 - 2021.
This narrative review compiled articles on Pneumococcus from January 2005 to October 2021, sourcing literature from databases such as BIOSIS Preview, CAB Direct, Embase, Google Scholar, and others.
In the Philippines, there was a shift in prevalent serotypes of among children under five following the introduction of PCV13 in the National Immunization Program in 2014, with serotype 14 becoming the most common by 2018, and a significant reduction in isolates reported in 2020, where only serotypes 5, 19A, and 23F were identified among invasive strains. The immunogenicity results of a potential vaccine candidate should be factored into the overall evidence when conducting a reassessment of PCV.
As part of the decision making about the inclusion of the PCVs in the NIP of the Philippines, various factors such as local epidemiology, vaccine supply, cost, and programmatic characteristics must be careful weighed. Enhancing laboratory and surveillance capacity are essential to provide evidence-based decision-making in terms of existing serotype distribution and antimicrobial resistance (AMR) profile in the country. With the introduction of a new affordable formulation of a 10-valent PCV offering a comparable serotype coverage, the reassessment of choice of PCV with the consideration of all three formulations, namely PCV13, PHiD-CV, and SIIPL-PCV, may be warranted.
肺炎球菌疫苗已被广泛用于预防肺炎球菌疾病，自2009年以来有两种类型的疫苗可供使用。随着世界卫生组织（WHO）建议在全球各国免疫规划（NIPs）中纳入肺炎球菌结合疫苗（PCVs），一种十价PCV（PHiD-CV）于2012年首次在菲律宾引入。然而，在2014年处方执行委员会提出建议后，该国转而使用13价PCV（沛儿）。
本综述旨在呈现2005年至2021年菲律宾国家免疫规划中肺炎球菌疾病及疫苗纳入情况的相关证据。
本叙述性综述收集了2005年1月至2021年10月有关肺炎球菌的文章，文献来源包括BIOSIS Preview、CAB Direct、Embase、谷歌学术等数据库。
在菲律宾，2014年国家免疫规划中引入PCV13后，五岁以下儿童中流行血清型发生了变化，到2018年血清型14成为最常见的血清型，2020年报告的分离株显著减少，在侵袭性菌株中仅鉴定出血清型5、19A和23F。在对PCV进行重新评估时，应将潜在疫苗候选物的免疫原性结果纳入整体证据中。
作为菲律宾国家免疫规划中是否纳入PCVs决策的一部分，必须仔细权衡各种因素，如当地流行病学、疫苗供应、成本和规划特点。加强实验室和监测能力对于根据该国现有的血清型分布和抗菌药物耐药性（AMR）情况提供循证决策至关重要。随着一种新的价格亲民的十价PCV制剂推出，其血清型覆盖率相当，考虑到PCV13、PHiD-CV和SIIPL-PCV这三种制剂，对PCV选择进行重新评估可能是必要的。
